ZNFX1 Inhibitors
Chemical inhibitors of ZNFX1 utilize various molecular mechanisms to impede the protein's function within cellular processes. Staurosporine acts as a general protein kinase inhibitor, targeting the enzymatic activity essential for the phosphorylation events that ZNFX1 relies on to fulfill its role in antiviral responses. This broad-spectrum inhibition can disrupt multiple kinase-dependent signaling pathways, thereby limiting ZNFX1's ability to mediate its effects. Similarly, Chelerythrine specifically targets Protein Kinase C (PKC), which is part of the signaling cascade that ZNFX1 may be involved in. By inhibiting PKC, Chelerythrine disrupts the phosphorylation required for the proper function of ZNFX1 in response to cellular stimuli. Furthermore, the inhibition of NF-kB signaling by JSH-23 and the irreversible inhibition of IKK by BAY 11-7082 result in suppressed expression of immune-responsive genes that ZNFX1 is likely to influence, thereby directly affecting ZNFX1's role in these pathways.
Additionally, several inhibitors target key components of transcription and signaling pathways that are upstream of ZNFX1 function. DRB hinders the action of RNA Polymerase II, thereby preventing the production of mRNA necessary for ZNFX1 synthesis. LY294002 and Wortmannin both inhibit the PI3K/AKT pathway, a crucial conduit for relaying signals that determine ZNFX1's involvement in antiviral responses. PD98059, U0126, SB203580, and SP600125 are specific inhibitors of the MAPK pathway components MEK, p38 MAP Kinase, and JNK, respectively. These inhibitors collectively block the activation of ERK, p38, and JNK, which are integral to the mediation of stress responses, including those to viral infection, where ZNFX1 is known to play a role. By preventing the activation of these kinases, these chemicals effectively impede the signal transduction that enables ZNFX1 to participate in managing cellular stress responses. Lastly, Rapamycin inhibits mTOR, a central player in cell growth and stress response pathways, which in turn, can limit the involvement of ZNFX1 in these processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. ZNFX1 plays a role in the antiviral response, which often involves signal transduction pathways that are dependent on protein kinase activity. By inhibiting these kinases, Staurosporine can inhibit the cellular signaling required for ZNFX1 to exert its function in the antiviral response. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA Polymerase II, which is pivotal in the transcription of mRNA for proteins including ZNFX1. Although not directly inhibiting ZNFX1, the inhibition of RNA Polymerase II will prevent the transcription of mRNA essential for ZNFX1 function. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 is an inhibitor of NF-kB signaling. ZNFX1 has been implicated in immune response modulation, where NF-kB plays a crucial role. Inhibiting NF-kB can suppress the expression of immune-responsive genes that ZNFX1 might influence. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits IKK, leading to inhibition of NF-kB activation. Given ZNFX1's involvement in immune response pathways, this inhibition can obstruct the pathway's function, thereby inhibiting ZNFX1's role in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which interrupts the PI3K/AKT pathway, a pathway that can regulate the antiviral response, where ZNFX1 is involved. Inhibition of this pathway can, therefore, inhibit the function of ZNFX1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which prevents activation of ERK MAP kinase. Since ZNFX1 is involved in the cellular response to viral infection, blocking the MEK/ERK pathway can inhibit ZNFX1's function in that response. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP Kinase, which is involved in stress responses in cells, including those to viral infection, where ZNFX1 has a role. Inhibiting p38 MAP kinase can inhibit ZNFX1's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. ZNFX1, being implicated in the cellular response to stress and infection, would have its function inhibited by blocking JNK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, leading to downstream inhibition of ERK activation. As ZNFX1 operates within cellular pathways that involve ERK signaling, inhibiting MEK1/2 would inhibit the function of ZNFX1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can inhibit the AKT pathway. By doing so, it can inhibit the signaling processes necessary for ZNFX1's function in the cellular antiviral response. | ||||||